Expression patterns of bone morphogenetic protein antagonists in colorectal cancer desmoplastic invasion fronts

被引:20
|
作者
Karagiannis, George S. [1 ,2 ]
Treacy, Ann [3 ]
Messenger, David [4 ,5 ]
Grin, Andrea [1 ,6 ]
Kirsch, Richard [1 ,2 ]
Riddell, Robert H. [1 ,2 ]
Diamandis, Eleftherios P. [1 ,2 ,7 ]
机构
[1] Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada
[2] Mt Sinai Hosp, Dept Pathol & Lab Med, Toronto, ON M5T 3L9, Canada
[3] Charlemont Clin, MC Pathol, Dublin, Ireland
[4] Mt Sinai Hosp, Zane Cohen Clin Res Ctr, Toronto, ON M5T 3L9, Canada
[5] Mt Sinai Hosp, Div Gen Surg, Toronto, ON M5T 3L9, Canada
[6] St Michaels Hosp, Dept Lab Med, Toronto, ON M5B 1W8, Canada
[7] Univ Hlth Network, Dept Clin Biochem, Toronto, ON, Canada
关键词
Bone morphogenetic; protein antagonists; Gremlin-1; Follistatin; High-temperature requirement-A3; Tumor budding; Cancer-associated fibroblasts; Colorectal cancer; MICROSATELLITE INSTABILITY; PROGNOSTIC MARKER; COLON; GENE; HISTOPATHOLOGY; FIBROBLASTS; PROGRESSION; METASTASIS; GREMLIN-1; CELLS;
D O I
10.1016/j.molonc.2014.04.004
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Bone morphogenetic proteins (BMPs) are a group of growth factors with dual functions in cancer development and progression. Recently, certain tumor-promoting roles have been identified for selected antagonists/inhibitors (BMPIs) of this developmental pathway. A recent focus on the implication of BMP in colorectal cancer progression has emerged, mainly due to the presence of inactivating mutations in several members of the canonical signaling cascade. However, the detailed expression profiles of BMPIs remain largely unknown. Based on our previous work, whereby three specific BMPIs, gremlin-1 (GREM1), high-temperature requirement A3 (HTRA3) and follistatin (FST) were collectively overexpressed in desmoplastic cocultures of colorectal cancer (CRC), here, we undertook an immunohistochemical approach to describe the patterns of their expression in CRC patients. Two major characteristics described the BMPI expression signature: First, the synchronous and coordinated stromal and epithelial overexpression of individual BMPIs in desmoplastic lesions, which demonstrated that all three of them contribute to increasing levels of BMP antagonism in such areas. Second, the presence of microenvironmental polarity in the BMPI pattern of expression, which was indicated through the preferential expression of HTRA3 in the stromal, and the parallel FST/GREM1 expression in the epithelial component of the investigated sections. In addition, expression of HTRA3 in the epithelial compartment of the tumors demonstrated a significant predictive power to discriminate between tumor-budding-bearing and tumor-budding-free desmoplastic microenvironments. Together, these findings contribute to the understanding of signaling dynamics of BMP antagonism in the colorectal cancer desmoplastic invasion front. (C) 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:1240 / 1252
页数:13
相关论文
共 50 条
  • [21] Methylation of bone morphogenetic protein 2 is associated with poor prognosis in colorectal cancer
    Miura, Tomiyuki
    Ishiguro, Megumi
    Ishikawa, Toshiaki
    Okazaki, Satoshi
    Baba, Hironobu
    Kikuchi, Akifumi
    Yamauchi, Shinichi
    Matsuyama, Takatoshi
    Uetake, Hiroyuki
    Kinugasa, Yusuke
    ONCOLOGY LETTERS, 2020, 19 (01) : 229 - 238
  • [22] Enrichment map profiling of the cancer invasion front suggests regulation of colorectal cancer progression by the bone morphogenetic protein antagonist, gremlin-1
    Karagiannis, George S.
    Berk, Aaron
    Dimitromanolakis, Apostolos
    Diamandis, Eleftherios P.
    MOLECULAR ONCOLOGY, 2013, 7 (04): : 826 - 839
  • [23] Lack of expression of extracellular antagonists of the bone morphogenetic and Wnt protein families is a determinant of the osteoblast response in bone metastasis
    Schwaninger, R.
    Rentsch, C. A.
    Wetterwald, A.
    Van Der Horst, G.
    Van Bezooijen, R.
    Van Der Pluijm, G.
    Lowik, C.
    Ackermann, K.
    Pyerin, W.
    Hamdy, F.
    Cecchini, M. G.
    Thalmann, G. N.
    EUROPEAN UROLOGY SUPPLEMENTS, 2006, 5 (14) : 795 - 795
  • [24] Differential gene expression and regulation of the bone morphogenetic protein antagonists follistatin and gremlin in normal and osteoarthritic
    Tardif, G
    Hum, D
    Pelletier, JP
    Boileau, C
    Ranger, P
    Martel-Pelletier, J
    ARTHRITIS AND RHEUMATISM, 2004, 50 (08): : 2521 - 2530
  • [25] Differential expression and regulation of bone morphogenetic protein 7 in breast cancer
    Schwalbe, M
    Sänger, J
    Eggers, R
    Naumann, A
    Schmidt, A
    Höffken, K
    Clement, JH
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2003, 23 (01) : 89 - 95
  • [26] Increased expression of bone morphogenetic protein-7 in bone metastatic prostate cancer
    Masuda, H
    Fukabori, Y
    Nakano, K
    Takezawa, Y
    Suzuki, T
    Yamanaka, H
    PROSTATE, 2003, 54 (04): : 268 - 274
  • [27] Bone morphogenetic protein gene expression patterns are altered by physiological and pharmacological regulators of bone metabolism.
    Zhang, M
    Maran, A
    Evans, GL
    Kennedy, AM
    Turner, RT
    JOURNAL OF BONE AND MINERAL RESEARCH, 2002, 17 : S431 - S431
  • [28] Bone morphogenetic protein and growth differentiation factor cytokine families and their protein antagonists
    Rider, Christopher C.
    Mulloy, Barbara
    BIOCHEMICAL JOURNAL, 2010, 429 : 1 - 12
  • [29] The bone morphogenetic protein pathway is active in human colon adenomas and inactivated in colorectal cancer
    Kodach, Liudmila L.
    Bleurning, Sylvia A.
    Musler, Alex R.
    Peppelenbosch, Maikel R.
    Hommes, Daniel W.
    van den Brink, Gijs R.
    van Noesel, Carel J. M.
    Offerhaus, G. Johan A.
    Hardwick, James C. H.
    CANCER, 2008, 112 (02) : 300 - 306
  • [30] Bone morphogenetic protein-4 polymorphism and colorectal cancer risk: a meta analysis
    Li, Jin
    Sun, Chuang
    Yuan, Yuerong
    Liu, Li
    Xiong, Guanglian
    Wu, Jing
    MOLECULAR BIOLOGY REPORTS, 2012, 39 (05) : 5239 - 5251